At Centrexion Therapeutics, we believe that we have one of the industry’s largest pipelines of novel, non-opioid clinical stage product candidates for the treatment of chronic pain. Our product candidates are designed to work on multiple types of chronic pain, including that of neuropathic and inflammatory origin, which are associated with a wide variety of diseases where pain is a co-morbid condition. We believe that our broad therapeutic pipeline of non-opioid chronic pain therapeutics is uniquely positioned to address the limitations of currently-available therapies by providing safe, effective and durable pain treatment solutions, as well as treat chronic pain as the disease itself, rather than as a symptom.
The company’s lead product candidate, CNTX-4975, has been shown in clinical studies to provide significant and durable relief from localized moderate to severe knee OA pain by the second day.
Licensing deal with Lilly
CNTX-0290 is an investigational small molecule SSTR4 agonist for chronic pain.
CNTX-6970 is a novel, potent and selective investigational small molecule CCR2 antagonist administered orally for the treatment of inflammatory chronic pain.
CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine with the potential to address pain across a broad range of indications, including superficial musculoskeletal pain, dermatologic itch and pain, as well as superficial neuropathic pain.
CNTX-6016 is a cannabinoid agonist that has been shown in preclinical studies to be more than 16,000-fold selective for CB2 over CB1, with potential indications including diabetic and autoimmune neuropathic pain and chemotherapy-induced neuropathy.